4.8 Article

Early chronic obstructive pulmonary disease: definition, assessment, and prevention

期刊

LANCET
卷 385, 期 9979, 页码 1778-1788

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/S0140-6736(15)60647-X

关键词

-

资金

  1. American Board of Internal Medicine
  2. Almirall
  3. APT Pharma
  4. American Thoracic Society
  5. AstraZeneca
  6. Baxter
  7. Boerhinger Ingelheim
  8. Chiesi
  9. Cipla
  10. Cleveland Clinic
  11. COPD Foundation
  12. CSA
  13. CSL
  14. California Thoracic Society
  15. Daiichi Sankyo
  16. Elevation Pharma
  17. Forest
  18. GSK
  19. Gilead
  20. Johnson Johnson
  21. MedImmune
  22. Novartis
  23. Pearl
  24. Pfizer
  25. Pulmatrix
  26. Regeneron
  27. Takeda
  28. Theron
  29. National Heart, Lung and Blood Institute
  30. Nebraska Department of Health and Human Services
  31. National Institutes of Health

向作者/读者索取更多资源

Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide. COPD, however, is a heterogeneous collection of diseases with differing causes, pathogenic mechanisms, and physiological effects. Therefore a comprehensive approach to COPD prevention will need to address the complexity of COPD. Advances in the understanding of the natural history of COPD and the development of strategies to assess COPD in its early stages make prevention a reasonable, if ambitious, goal.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据